Notice ID: 92b8bff493b2450ea5ce96a1c40a1608JustificationAwardedArchived
JEFO: Medical Supply Cabinets
Awarded on March 26, 2026. Full description on SAM.gov.
Overview
- Posted
- March 31, 2026
- Notice type
- Justification
- NAICS
- 334510: Electromedical and Electrotherapeutic Apparatus Manufacturing
- Agency
- Department of WarDEFENSE LOGISTICS AGENCY
Notice details
- Office
- TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT
- Place of performance
- Michigan, 48025
- Last updated
- Nov 1, 2026
- First published
- Last updated on SAM.gov
- Award date
- Mar 26, 2026
- Award amount (SAM.gov award notice)
- Not specified
Identifiers
- Solicitation number
- SPE2D5-26-F-019T
- Notice ID
- 92b8bff493b2450ea5ce96a1c40a1608
Description
See attached JEFO.
Award Overview
Award Number
SPE2D1-21-D-7004
Award Amount (SAM.gov award notice)
Not specified
Award Date
Mar 26, 2026
Awardee
Not specified
Delivery Order Number
SPE2D5-26-F-019T
Original Solicitation
Notice ID: 92b8bff493b2450ea5ce96a1c40a1608
Posted Date: Mar 31, 2026
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $746.9KSigned Dec 2, 2025
- $652.0KSigned Apr 24, 2026
- $397.9KSigned Mar 26, 2026
- $335.8KSigned Jul 20, 2026
- $319.5KSigned Aug 10, 2026
- $311.1KSigned Jul 23, 2026
- $311.1KSigned Aug 3, 2026
- $311.1KSigned Jun 24, 2026
- $297.3KSigned May 19, 2026
- $274.1KSigned Feb 3, 2026
More From This Vendor
Top 5 most recent
- $88.4Signed Aug 17, 2026
- $137.5KSigned Aug 17, 2026
- $1.2KSigned Aug 17, 2026
- $2.0KSigned Aug 14, 2026
- $155.6KSigned Aug 14, 2026
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
ECAT JEFO Trillamed OmnicellXT_FINAL 30 MAR 2026_REDACTED.pdf
380 KBAdded in Justification version 3Posted
Lifecycle
- 3Version 3JustificationArchivedCurrent
JEFO: Medical Supply Cabinets
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Defense Logistics Agency, Troop Support, Philadelphia, PA Medical Directorate intends to award a Firm Fixed Price, Sole Source contract under the authority of FAR 12.102(a) to Carahsoft Technology Corp, on behalf of Nuance, address 11493 Sunset Hills Road, Reston, VA 20190, for the procurement of the following brand name post warranty maintenance, updates, and software licensing Product: PowerScribe 360 post warranty maintenance, software licenses This award for brand name software licenses and post warranty maintenance will be placed on a sole source basis with Carahsoft, on behalf of Nuance, as the following circumstance in FAR 12.102(a) applies: only one source is available to provide the services required at the level of quality required because the services are unique or highly specialized. The PowerScribe software is proprietary software developed and provided exclusively by Nuance. The software licensing is for the PowerScribe 360 brand name voice dictation systems already in place at the required site, Fort Belvoir, Virginia. The absence of post warranty maintenance, updates and software licensing will cause significant work-stoppage for voice dictation for radiology systems. Thus, only the exact brand name maintenance and licenses will meet the customer's needs. Delivery schedule will be discussed prior to issuing the award. The anticipated award date is December 2, 2026. This notice is not a request for competitive quotes; however, that all responsible sources and interested parties may identify their interest and capability to meet the requirements by submitting technical data for this requirement data within fifteen calendar days of this notice posting (no later than November 18, 2026), by 2:00 PM EST, to Marco Sifoni, via email at marco.g.sifoni@dla.mil, which shall be considered by the agency. Please note telephone calls will not be honored. DLA Troop Support intends to solicit this requirement in accordance with FAR 12.201-1(c)(2), thus no written solicitation will be issued. ***Paragraph three was updated on Wednesday November 4th, 2026 to edit the error of calendar days stated previously from seven days to fifteen days.*** | 68% | Pre-Solicitation | 11/18/2026 |
This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. Solicitation number SPE2D1-27-R-0001 is issued as a request for proposal (RFP) for Digital Imaging Network - Picture Archiving and Communication Systems (DIN-PACS) - Generation V. This acquisition is not a set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. DLA Troop Support and the Veterans Administration (VA) National Acquisition Center (NAC) are requesting offers for commercial products and components in the following Digital Imaging Network - Picture Archiving and Communications Systems (DIN-PACS) specialties: (a) Cardiology (b) Dental (c) Dermatology (d) Endoscopy (e) Nuclear Medicine (f) OB/GYN (g) Oncology (h) Ophthalmology (i) Pathology (j) Point of Care Ultrasound (POCUS) (k) Radiology (l) Sleep Lab (m) Veterinary (n) Vendor Neutral Archive (VNA) Offers will be accepted through October 14, 2033 at 3:00PM Eastern Daylight Time (EDT). | 68% | Combined Synopsis | 10/14/2031 |
VA has identified Cochlear Implants (CI) and Auditory Osseointegrated Implants (AOI) and related products/supplies/accessories as a continued requirement in support of both VA and the Department of Defense (DoD) approved medical facilities. Cochlear Implants and Auditory Osseointegrated Implants are currently provided through multiple firmfixed price, indefinite delivery/indefinite quantity (IDIQ) contracts. These current contracts are managed by the Denver Logistics Service (DLS) and administered by the Commodities and Services Acquisition Service (CSAS) in support of the Prosthetic and Sensory Aids Services (PSAS). The purpose is to define the requirements for Auditory Implant systems (CIs and AOIs), replacement parts and accessories compatible with CIs and AOIs to both the VA and DoD. The VA has identified OEM customized (prescription) implants, processors, wireless devices, and accessories. as preferred products for this contract. The objectives are to: 1. Establish multiple sole-source awarded contracts that can serve the entire United States and its territories for customized (prescription) auditory implants and repairs to eligible Veterans and beneficiaries using standardized ordering processes. 2. Obtain quality products at a significant discount compared to the commercial market prices. 3. Ensure availability and consistency of products for nationwide usage while integrating the DLS Remote Order Entry System (ROES) program for ordering. VA Audiologists shall order auditory implant contracted line items through the national ROES. 4. Improve operating efficiency throughout the VA. 5. This contract will also allow for higher level of effective communication between the Government and the Contractor, which is essential for partnering for this performance-based contract to succeed. The success of this contract is mutually erected through good communication between the Government and the Contractor. ndefinite Delivery Indefinite Quantity (IDIQ) contract(s) will be for a oneyear base period and nine (9) one-year option periods. and will be used as a primary source by the VA. Other approved Government agencies are the Department of Defense (DoD) and Indian Health Services (IHS) will be authorized and able to procure contract line items by placing orders directly utilizing contractors’ commercial system. Option periods will or will not be exercised at the sole discretion of the Government. This contract was awarded as a FFP IDIQ Sole Source award. | 57% | Awarded | Open |
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Revolutionary Federal Acquisition Regulation (FAR) Overhaul (RFO) 12.2, “Solicitation, Evaluation, and Award,” as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a written solicitation will not be issued. See attachments for details | 57% | Combined Synopsis | 12/15/2026 |
Amendment 1 11/19/2026 Adds Response Form. No changes to response date. The Center for Biomedical Advanced Research and Development Authority (BARDA) intends to use responses to this Sources Sought Notice (SSN) for planning purposes. BARDA will not award any contracts under this Notice, but rather seeks current and forecasted prices, inventories, capabilities, and other pertinent marketplace data. This Notice is issued by the Center for Biomedical Advanced Research and Development Authority (BARDA) to identify innovative medical countermeasure technologies to enable rapid triage of musculoskeletal injuries such as fractures and soft tissue injuries of extremities. This request is for information only and is intended to assess the current state of commercially available technologies and technologies nearing commercial availability that support automated ultrasound-based fracture detection using technologies commonly known as Artificial Intelligence (AI). Consistent with Executive Order 14434, “Inaugurating the Era of Super Intelligence,” AI- technologies are now referred to as Super Intelligence (SI) throughout this notice, including in the title and should be referred the same in the response. The Center for Biomedical Advanced Research and Development Authority (BARDA) intends to use responses to this Sources Sought Notice (SSN) to inform planning for the potential acquisition of ultrasound-based devices capable of capturing and displaying anatomical data. Potential acquisition and inventory approaches include device purchases or leases supported by vendor-managed inventory (VMI) arrangements. BARDA seeks information on technologies that could assist clinical care providers in visualizing or detecting musculoskeletal injuries, including fractures and soft tissue injuries, to support triage and initial treatment in emergency departments, urgent care centers, and field settings. These devices could also support continued evaluation and treatment in definitive orthopedic care settings, consistent with applicable regulatory authorizations and intended uses. The U.S. Department of Health and Human Services (HHS) leads Federal public health and medical preparedness and response efforts, including supporting the research, development, acquisition, and availability of medical countermeasures (MCMs). These efforts address the health consequences of chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases, including threats arising from deliberate, accidental, or naturally occurring events. This SSN supports planning for medical capabilities that could strengthen the Nation’s preparedness for and response to emergencies involving traumatic injuries. The Project BioShield Act of 2004 (Pub. L. No. 108-276) established authorities for procuring qualifying security countermeasures for the Strategic National Stockpile (SNS). The Pandemic and All-Hazards Preparedness Act of 2006 (Pub. L. No. 109-417) further strengthened the Nation’s medical countermeasure development and preparedness framework. The National Health Security Strategy 2023–2026 provides additional strategic context for strengthening preparedness, response, and recovery capabilities. Consistent with these preparedness objectives, this Sources Sought Notice seeks information on potential approaches to improve the availability and accessibility of relevant medical devices across health care settings. Approaches of interest include purchase, lease, vendor-managed inventory (VMI), and arrangements that combine access to devices with maintenance and readiness support. Information received will inform acquisition planning and assessment of these approaches, subject to applicable statutory authorities, acquisition requirements, and availability of funds. These documents represent the foundation for addressing the Nation’s CBRN MCM needs. Amongst the foundational documents referenced above, musculoskeletal injuries such as fractures resulting from nuclear blast explosions and structural collapse, as well as and other mass casualty events present significant challenges in both field and clinical settings which require prompt diagnosis for adjudication and triage of patients. Current standards of care rely heavily on radiography and CT imaging, which are often unavailable, delayed, or resource-constrained in austere environments, disaster response settings, or during patient surge conditions. Delayed or missed fracture diagnosis can worsen patient outcomes and burden downstream care. BARDA is seeking solutions that enhance the speed, accuracy, and accessibility of fracture detection at the point of injury and point of care, without dependence on traditional imaging infrastructure. CAPABILITY STATEMENT/INFORMATION SOUGHT This Sources Sought Notice (SSN) seeks information from small business (SB) and other than small business (OTSB) concerns regarding their qualifications, experience, and capabilities to develop, manufacture, and deploy standalone, point-of-care, super intelligence (SI)-enabled ultrasound devices for fracture detection. Respondents shall provide only the information, data, and materials necessary to demonstrate their capabilities relevant to this notice. Responses shall include separate Technical Representation and Business Representation sections, as detailed below. Each section shall not exceed 10 single-sided pages, including all attachments, résumés, charts, and other supporting materials, and shall use 12-point Times New Roman font. Pages exceeding the limit for either section will not be reviewed. Respondents shall identify their business size status as either small business or other than small business under the NAICS code and corresponding size standard identified in this notice. Technical Representations Respondents shall provide the technical information requested by ASPR/BARDA in separately numbered sections, in the order listed below. For any section that does not apply, respondents shall retain the section number and heading, mark it “Not Applicable,” and briefly explain why it does not apply. Response Specification In response to this notice, clearly describe the capability and experience that meets the criteria specified in the subsequent categories. A template is provided for detailed and concise responses as related to the qualifying criteria. Additional supporting evidence, data, and information can be provided as attachments, not to exceed the 10-page limit per submission to this notice. All sponsors responding to this notice are required to provide the requested information on their products and capabilities by providing short responses, summarizing their device's diagnostic capability along with performance data, TRL and development status, regulatory documentation, product IFU, manufacturing overview, and supply-chain and production information. The narrative response to the templated prompts may include figures, schematics, diagrams, photographs, etc. and shall describe the proposed final product under consideration. Any proposed device must qualify against the following criteria (either work completed or demonstratable work in progress): Display and Diagnostic of Anatomy for Fracture Evaluation Capability Automated ultrasound imaging-based volumetric capture and display of detailed anatomy of different structures and providing bone detection/identification in areas such as wrist, ankles and others; and assist care providers to visualize clinically significant injuries such as fractures. Embedded ultrasound image processing information with appropriately trained Super Intelligence and machine learning (SI/ML) models to assist in image acquisition and segmentation for data interpretation with predefined sensitivity/specificity performance, which has been reviewed and adjudicated in FDA submissions for 510k clearance process. Models must be rigorously tested/validated against independent datasets separate from their training and their performance must improve upon that of human imaging experts. Capability either established or under development to distinguish different degrees / types of fracture and severity where it is deemed clinically appropriate, presence of edema or soft-tissue injuries. Capability to reconstruct and render 3D-rotatable models/ cross-sectional data review based on the captured ultrasound volumetric visualization of the bone and render the detection of injury and/or anatomy of the investigational areas for clinician adjudication. Use of color overlays for various anatomies and layers is ideal Performance comparison data against standard established technologies such as X-ray radiographic images or CT images. Desirable Device Design and Portability Characteristics Standalone, point-of-care form factor with integrated SI-processing. Units to be durable/ruggedized for field and disaster-response conditions Self-contained (e.g. all supplies and imaging media/gels sprays/wipes) all in a single portable unit which if required is field-deployable based on weight and size Battery life and power requirements suitable for use even under austere environments Ability to export and save data and link to EHR-systems within hospitals to enable billing and reimbursement. Interoperability with EHR or existing triage/documentation systems Use-Case Flexibility Operable in both field/austere environments and general clinical/hospital settings Minimal training burden for non-specialist operators (e.g., combat medics, first responders, general clinical technicians) Functions independently when a reliable network connectivity is unavailable Compatible with hospital ED workflows in rural and urban settings, use in urgent care centers and compatible with mass casualty triage workflows Development Status: Clinical and Regulatory Maturity Summary of advanced development pathway including various testing and validation performed; preclinical, clinical testing (MRMC, human factors) as well as bench testing. Regulatory Status: Pathway for product clearance/ approval as envisioned. Support this with a summary of pre-submission, FDA breakthrough designation efforts whether received or not, ongoing questions pending with FDA and/or feedback received. Any relevant work conducted under Department of War (DoW) or other federal agency Key technical risks identified, and mitigation plans Scalability and Manufacturing and Supply Chain Management / Resilience U.S. domestic maximum manufacturing capability and inventory management and warehousing strategy An established manufacturing process which covers required quality and ISO systems for GMP manufacture using reproducible, scalable processes with relevant operational certification from FDA and other regulatory bodies as a result of successful audits and accreditations. Strategy to establish supply chain resilience for all hardware and electronic components, sensors, transducers etc. critical for manufacture of the product. Cyber security and data storage and management security standards and certifications. List capability and testing for handling of sensitive patient PII and health information security and safeguards and transfer to other required systems such as electronic health records. Indicated Population and Use Cases Broad applicability across adult and pediatric patient populations Applicable to blast injuries, blunt trauma, structural collapse, and other mass casualty fracture presentations. Demonstrated or anticipated performance across a range of fracture types and anatomical locations. Response Format, Transmission, and Closing Date Respondents shall submit declarations of capability and all supporting information, data, and materials in Microsoft Office® or Adobe® Acrobat® format via email to Justin.Moore@hhs.gov and Richard.hall@hhs.gov. Responses must be received no later than 1:00 p.m. Eastern Time (ET) on November 18, 2026. All questions, comments, or concerns regarding this notice shall be submitted in writing to the same email address. | 57% | Market Research | 11/18/2026 |
Additional Details
Solicitation Number
SPE2D5-26-F-019T
Archive Date
Apr 30, 2026
Office Address
PHILADELPHIA, PA, 19111